(Q36624187)

15 August 2017

A phase I dose-escalating study of DaunoXome, liposomal daunorubicin, in metastatic breast cancer (English)

1 reference

15 August 2017

metastatic breast cancer

1 reference

1 reference

K J O'Byrne

1

1 reference

15 August 2017

A L Thomas

2

1 reference

15 August 2017

R A Sharma

3

1 reference

15 August 2017

M DeCatris

4

1 reference

15 August 2017

F Shields

5

1 reference

15 August 2017

S Beare

6

1 reference

15 August 2017

W P Steward

7

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 July 2002

1 reference

British Journal of Cancer

15 August 2017

1 reference

15 August 2017

87

1 reference

15 August 2017

1

1 reference

15 August 2017

15-20

1 reference

Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

Pharmacokinetics of liposomal daunorubicin (DaunoXome) during a phase I-II study in children with relapsed acute lymphoblastic leukaemia

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

A phase II study of DaunoXome in advanced urothelial transitional cell carcinoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimens

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

Phase I and pharmacologic study of liposomal daunorubicin (DaunoXome).

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

Randomized phase II trial of carminomycin versus 4'-epidoxorubicin in advanced breast cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

Early and delayed clinical cardiotoxicity of doxorubicin

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

New anthracycline analogs in advanced breast cancer

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

Selective in vivo localization of daunorubicin small unilamellar vesicles in solid tumors

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

Liposomal doxorubicin and weekly paclitaxel in the treatment of metastatic breast cancer.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

Phase III comparative study of vinorelbine combined with doxorubicin versus doxorubicin alone in disseminated metastatic/recurrent breast cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

Fluorescence imaging studies for the disposition of daunorubicin liposomes (DaunoXome) within tumor tissue.

20 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2364277

Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial

20 September 2018

1 reference

Crossref

https://api.crossref.org/works/10.1038%2FSJ.BJC.6600344

[Administration of liposomal preparation of DaunoXome for breast cancer in patients with poor prognosis]

21 January 2018

1 reference

12 December 2020

Phase I study of Doxil and vinorelbine in metastatic breast cancer

1 reference

12 December 2020

A dose-finding study of liposomal daunorubicin with CVP (COP-X) in advanced NHL

1 reference

12 December 2020

Anthracycline Efficacy in vitro: Cytotoxicity of Liposomal/Nonliposomal Daunorubicin and Doxorubicin for Multiple Tumor Cell Types

1 reference

12 December 2020

A prospective randomized trial of doxorubicinversus idarubicin in the treatment of advanced breast cancer

1 reference

12 December 2020

Continuous venous infusion of doxorubicin in advanced sarcomas

1 reference

12 December 2020

Use of daunorubicin in patients with solid tumors

1 reference

12 December 2020

A phase I study of daunorubicin in advanced untreatable malignancies

1 reference

12 December 2020

Clinical pharmacology of daunorubicin in phase I patients with solid tumors: development of an analytical methodology for daunorubicin and its metabolites

1 reference

12 December 2020

Cardiac effects of anthracyclines used in the treatment of childhood acute lymphoblastic leukemia: a 10-year experience

1 reference

12 December 2020

Potential of liposomes to ameliorate anthracycline-induced cardiotoxicity

1 reference

12 December 2020

Cardiotoxicity of adriamycin and related anthracyclines

1 reference

12 December 2020

DaunoXome shows promise as breast cancer treatment

1 reference

12 December 2020

Early evaluation of liposomal daunorubicin (DaunoXome, Nexstar) in the treatment of relapsed and refractory lymphoma

1 reference

12 December 2020

Drug delivery and targeting

1 reference

12 December 2020

Identifiers

DOI

10.1038/SJ.BJC.6600344

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

12085249

1 reference